drugset / Trial / NCT03631355

Reducing Hemarthrosis in ACL Reconstruction With BTB Autograft by the Administration of Intravenous TXA

NCT03631355

Phase 4 Completed 110 enrolled NYU Langone Health
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the proposed study is to evaluate the effects of administering intravenous tranexamic acid (TXA) to patients undergoing anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone autograft to minimize hemarthrosis within the knee joint and post operative pain.

Timeline

Start
2018-06-06
Primary completion
2020-03-01
Completion
2020-03-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tranexamic Acid Small molecule 1 g Intravenous

Indications

No indication recorded.